2-chlorobicyclo[4.2.0]octa-1,3,5-triene-7-carboxylic acid | 135634-40-1

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 芳基卤化物
• 英文名称: 2-chlorobicyclo[4.2.0]octa-1,3,5-triene-7-carboxylic acid
• 英文别名: 3-chloro-1,2-dihydrocyclobutabenzene-1-carboxylic acid；(3-chlorobenzocyclobutan-1-yl)-carboxylic acid；2-Chlorobicyclo[4.2.0]octa-1(6),2,4-triene-7-carboxylic acid
• CAS: 135634-40-1
• 化学式: C₉H₇ClO₂
• 分子量: 182.606
• InChiKey: HICLKCKBGFUQCW-UHFFFAOYSA-N

物化性质

• 沸点：
  347.6±42.0 °C(Predicted)
• 密度：
  1.460±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-chlorobicyclo[4.2.0]octa-1,3,5-triene-7-carboxylic acid 在 戴斯-马丁氧化剂 、 1-丙基磷酸酐 、 三乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 为溶剂， 反应 23.0h， 生成
  参考文献：
  名称：

  Synthesis of hexahydro[2]benzopyrano[4,3-c]pyridines as serotonin 5-HT2C receptor agonists via intramolecular hetero Diels–Alder reactions

  摘要：

  Hexahydro[2]benzopyrano[4,3-c]pyridines were synthesized by an intramolecular hetero Diels-Alder reaction. The reaction was applicable to a range of substrates and the products could be easily converted into serotonin 5-HT2C receptor agonists. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2011.03.054
• 作为产物：
  描述：

  3-(2,6-dichlorophenyl)propanenitrile 在 氨 、 水 、 sodium amide 、 potassium hydroxide 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 5.5h， 生成 2-chlorobicyclo[4.2.0]octa-1,3,5-triene-7-carboxylic acid
  参考文献：
  名称：

  Synthesis of hexahydro[2]benzopyrano[3,4-c]pyrroles as serotonin 5-HT2C receptor agonists via intramolecular hetero Diels–Alder reactions

  摘要：

  [2]Benzopyrano[3,4-c]pyrroles were synthesized via an intramolecular hetero Diels-Alder reaction. The reaction was applicable to a wide range of substrates and the products could be easily converted into serotonin 5-HT2c receptor agonists. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2011.03.055

文献信息

• [EN] TRICYCLIC HETEROCYCLIC DERIVATIVES<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES TRICYCLIQUES
  申请人：ORGANON NV

  公开号：WO2009037220A1

  公开（公告）日：2009-03-26

  The present invention relates to a tricyclic heterocyclic derivative of Formula (I) wherein the variables are as defined in the specification. The present invention further relates to pharmaceutical compositions comprising these compounds and to their use in therapy, in particular for the treatment of serotonin-mediated disorders such as obesity, schizophrenia and cognitive dysfunction.

  本发明涉及式(I)所示的三环杂环衍生物，其中变量如说明书中所定义。本发明进一步涉及包含这些化合物的药物组合物及其在治疗中的应用，特别是用于治疗由血清素介导的疾病，如肥胖、精神分裂症和认知功能障碍。
• [EN] NOVEL SUBSTITUTED N'-HYDROXYCARBAMIMIDOYL-1,2,5-OXADIAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS DE N'-HYDROXYCARBAMIMIDOYL -1,2,5-OXADIAZOLE SUBSTITUÉS EN TANT QU'INHIBITEURS DE L'INDOLÉAMINE 2,3-DIOXYGÉNASE (IDO)
  申请人：MERCK SHARP & DOHME

  公开号：WO2018044663A1

  公开（公告）日：2018-03-08

  Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Formula (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

  本文揭示了化合物的化学式(I)，或其药学上可接受的盐：化学式(I)。本文还揭示了所述化合物在潜在治疗或预防IDO相关疾病或紊乱中的用途。本文还揭示了包含所述化合物的组合物。本文还揭示了所述组合物在潜在治疗或预防IDO相关疾病或紊乱中的用途。
• Tricyclic heterocyclic derivatives
  申请人：Davies Keneth

  公开号：US08729274B2

  公开（公告）日：2014-05-20

  The present invention relates to a tricyclic heterocyclic derivative according to Formula (I), wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to pharmaceutical compositions comprising said tricyclic heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of serotonin mediated disorders, such as obesity.

  本发明涉及一种三环杂环衍生物，其符合公式（I）中定义的变量，或其药学上可接受的盐或溶剂。本发明还涉及包含所述三环杂环衍生物的制药组合物，并且它们在治疗中的应用，例如用于治疗或预防由血清素介导的疾病，如肥胖症。
• Substituted n′-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10988487B2

  公开（公告）日：2021-04-27

  Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Formula (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

  本文公开了一种式 (I) 的化合物或其药学上可接受的盐：式 (I)。本文还公开了本文公开的化合物在潜在治疗或预防 IDO 相关疾病或紊乱中的用途。本文还公开了包含本文公开的化合物的组合物。本文进一步公开了这些组合物在潜在治疗或预防 IDO 相关疾病或紊乱中的用途。
• Characterization of Potent and Selective Antagonists at Postsynaptic 5-HT1A Receptors in a Series of N4-Substituted Arylpiperazines
  作者：Jean-Louis Peglion、Herve Canton、Karin Bervoets、Valerie Audinot、Mauricette Brocco、Alain Gobert、Sylvie Le Marouille-Girardon、Mark J. Millan

  DOI：10.1021/jm00020a020

  日期：1995.9

  Benzocycloalkyl and benzocycloalkenyl moities linked, directly or via an alkyl chain, to oxygen-bearing heteroarylpiperazines were synthesized, in an attempt to obtain potent and selective antagonists at postsynaptic 5-HT1A receptors. From the numerous arylpiperazines described in the literature, 1-(2,3-dihydro-1,4-benzodioxin-5-yl)pipe (3a) was chosen as a model of an arylpiperazine in view of its selectivity for 5-HT1A receptors versus alpha(1)-, alpha(2)-, and beta-adrenergic receptors, as well as dopamine D-1 and D-2 receptors. Two other closely-related arylpiperazines, 1-(1,5-benzodioxepin-6-yl)piperazine (3b) and 1-(benzofuran-7-yl)piperazine (3c), were also examined in this study. Al compounds showed high affinity at 5-HT1A sites (8.10 less than or equal to pK(i)s less than or equal to 9.35), and the majority behaved as antagonists in vivo in blocking the hypothermia induced by the 5-HT1A agonist 8-OH-DPAT in the absence of a marked effect alone at equivalent doses. An in vivo evaluation of dopamine D-2 receptor antagonist properties revealed that the majority of compounds was devoid of activity at this site, in marked contrast to BMY 7378 which displayed virtually no selectivity for 5-HT1A versus dopamine D-2 receptors. Moreover, six compounds of the present series, 8, 10, 11, 14, 25, and, 37, showed > 10-fold selectivity in vitro for 5-HT1A versus alpha(1)-adrenergic receptors. Compound 14 displayed an optimal compromise between potency (pK(i) = 8.75), marked antagonist activity, and selectivity toward alpha(1)-adrenergic (81-fold) and dopamine D-2 (195-fold) receptors. These characteristics clearly distinguish 14 from previously-reported ligands such as the postsynaptic 5-HT1A antagonist BMY 7378 and the weak partial agonist NAN 190 which, in contrast to the compounds of this series, belong to the well-exemplified class of imido derivatives of (o-methoxyphenyl)piperazines. The availability of 14 (S 15535) should facilitate the further elucidation of the functional role and potential therapeutic significance of 5-HT1A receptors.